期刊
CANCER RADIOTHERAPIE
卷 23, 期 6-7, 页码 662-665出版社
ELSEVIER
DOI: 10.1016/j.canrad.2019.07.157
关键词
Chemoradiotherapy; Cisplatin; Cetuximab
Chemoradiotherapy is now considered the standard of care for many locally advanced diseases. Cytotoxic drugs have been largely evaluated in this setting, with cisplatin and 5FU the most often used drugs. A large amount of pre-clinical studies has demonstrated the synergy between both modalities. Concomitant administration seems the more beneficial in many diseases. Emergence of new approaches, combining targeted therapies and radiotherapy (RT) is now a reality. The main example is the association of cetuximab and RT in head and neck carcinomas, even if, 14 years after the initial publication, the best way to use it is still unknown. New compounds as inhibitors of DNA-repair or immune checkpoints are under investigation and showed early promising results. (C) 2019 Published by Elsevier Masson SAS on behalf of Societe francaise de radiotherapie oncologique (SFRO).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据